Last updated: February 20, 2026
Sensipar (cinacalcet) is a calcimimetic agent used primarily to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and to manage hypercalcemia in patients with parathyroid carcinoma.
Major Suppliers and Manufacturers of Sensipar
1. Amgen Inc.
- Market Presence: Amgen is the original developer and primary supplier of Sensipar.
- Manufacturing Details: Fully responsible for production, marketing, and distribution.
- Approval Status: FDA-approved in 2004; maintains global market licenses.
- Production Facilities: Multiple manufacturing sites globally, including in the United States and Ireland.
- Supply Chain Role: Dominant supplier worldwide, with a significant market share.
2. Other Contract Manufacturers
While Amgen holds the patent and primary market rights, third-party manufacturing becomes relevant in the context of generic versions or supply chain diversification.
-
Generic Manufacturers: As of the patent expiry or license agreements, generic producers may supply Sensipar or cinacalcet. Key generic manufacturers include:
- Teva Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Cipla
- Mylan (now part of Viatris)
-
Role: These manufacturers typically produce generic cinacalcet, which is chemically equivalent to Sensipar. However, they do not use the brand name Sensipar.
3. Regional Suppliers
Supply sources vary by country, especially where Amgen’s patent has expired or license agreements exist.
| Region |
Main Suppliers |
Notes |
| North America |
Amgen |
Exclusive rights; Amgen controls production and distribution. |
| Europe |
Amgen + Generics |
Amgen holds patent; generics entered post-patent expiry. |
| Asia |
Generics |
Multiple manufacturers supply cinacalcet as a generic. |
Licensing and Patent Status
-
Patent Expiry: Patents for Sensipar expired in most jurisdictions by 2017, enabling the entry of generic manufacturers.
-
Generic Market Entry: Post-2017, multiple generic producers gained approval, increasing supply options.
-
Supply Interruptions: Limited reports, but market dependence on Amgen can cause supply chain risks; generic proliferation has mitigated this.
Supply Chain Dynamics and Market Factors
- Pricing Influence: Patent exclusivity supported high pricing; generics introduced price competition.
- Regulatory Approvals: Generic manufacturers require approval under the abbreviated new drug application (ANDA) pathway in the U.S.
- Distribution Networks: Amgen has established global logistics; generic suppliers rely on regional distribution for market access.
Summary of Supplier Landscape
| Supplier Type |
Examples |
Market Share |
Notes |
| Original Manufacturer |
Amgen |
Approx. 100% (pre-2017) |
Monopoly until patent expiry. |
| Generics |
Teva, Dr. Reddy’s, Cipla, Viatris |
Significant post-2017 |
Competition drives pricing and supply diversification. |
Key Takeaways
- Amgen is the primary supplier of Sensipar; its monopoly lasted until patent expiration around 2017.
- Multiple generic manufacturers now supply cinacalcet, competing on price and availability.
- Regional differences influence supplier options, with generics dominating outside the U.S.
- Supply chain risk exists with reliance on Amgen; regional producers offer alternatives.
- Regulatory approval for generics is critical and varies by country, impacting supply options.
FAQs
Q1: Who was the original manufacturer of Sensipar?
A1: Amgen Inc.
Q2: Are there generic versions of Sensipar?
A2: Yes, several manufacturers produce generic cinacalcet following patent expiry.
Q3: Which regions have multiple suppliers for Sensipar?
A3: Europe, Asia, and other regions with approved generics. In the U.S., Amgen remains the primary source.
Q4: Has the supply of Sensipar been affected by patent expiration?
A4: Patent expiry has increased supply options; no widespread supply disruptions reported.
Q5: How do licensing agreements impact supply?
A5: They determine exclusivity periods; once expired, generic manufacturers enter the market, increasing supply.
References
[1] U.S. Food & Drug Administration. (2021). ANDA approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/andarecommendations
[2] Amgen Inc. Annual Report 2022.
[3] European Medicines Agency. (2022). Marketing authorizations. https://www.ema.europa.eu/en/medicines/human/EPAR/sensipar
